Em P Kevin Park

Professor Pharmacology & Therapeutics

Research

Research Group Membership

Research Grants

SMART STEP - Stepwise Translational Pathway for Smart Material Cell Therapy

MEDICAL RESEARCH COUNCIL (MRC)

September 2016 - August 2017

TransQST: Translational quantitative systems toxicology to improve the understanding of the safety of medicines

EUROPEAN COMMISSION

January 2017 - June 2022

Preclinical evaluation of Nrf2 inhibition as a means to improve chemotherapeutic efficacy in patients with pancreatic cancer

PANCREATIC CANCER RESEARCH FUND (UK)

February 2016 - January 2020

Development of a multicell model of human liver

WANNAN MEDICAL COLLEGE (CHINA)

January 2017 - December 2017

Mechanistic investigation and risk:benefit analysis of the use of brusatol as a novel adjuvant for overcoming cisplatin resistance in bladder cancer

NORTH WEST CANCER RESEARCH INCORPORATING CLATTERBRIDGE CANCER RESEARCH - NWCR (UK)

February 2016 - February 2018

Multi-modal high resolution preclinical PET+SPECT+CT scanner

WELLCOME TRUST (UK)

July 2018 - June 2023

Development of screening approaches to assess to intrinsic immunogenicity of drugs and novel chemicals

BIOTECHNOLOGY & BIOLOGICAL SCIENCE RESEARCH COUNCIL (BBSRC)

March 2018 - May 2021

To examine the potential preclinical value of mechanism-based biomarkers of DILI over more established and widely accepted clinical diagnostics related to liver histopathology. Development and qualification of the use of a combination of established and mechanism-based biomarkers (HMGB1(+Ac/-Ac); cytokeratin 18 or ccK18; Mir122) for DILI assay in preclinical studies (CDSS DILI Project)

MERCK & CO., INC. (USA)

February 2020 - February 2022

Understanding the heterogeneity of chronic lymphocytic leukaemia through the elucidation of how genetic alterations influence protein expression at the whole genome level.

NORTH WEST CANCER RESEARCH INCORPORATING CLATTERBRIDGE CANCER RESEARCH - NWCR (UK)

April 2016 - March 2019

A prospective investigation of β-lactam allergy in patients with cystic fibrosis to define drug immunogenicity

CYSTIC FIBROSIS TRUST (UK)

December 2011 - August 2016

Wellcome VIP

WELLCOME TRUST (UK)

July 2010 - September 2011

PAMPERS - Paediatric Accelerator Mass Spectrometry Evaluation Research Study

INSTYTUT FARMACEUTYCZNY (POLAND), MEDICAL RESEARCH COUNCIL (MRC)

September 2011 - December 2014

Quantitative high-throughput proteomics for biomedical research.

MEDICAL RESEARCH COUNCIL (MRC)

March 2005 - March 2008

Hepatocyte Phenotype Project: Phase II proposal

STEM CELLS FOR SAFER MEDICINES LTD (UK)

May 2011 - May 2014

Assessment of the impact of host genetic variation on the response to lopinavir-containing regimens in HIV+ patients.

WELLCOME TRUST (UK)

June 2005 - August 2005

The chemical and molecular basis of the prevention of drug-induced liver injury by Nrf2.

WELLCOME TRUST (UK)

January 2007 - December 2009

Novel testing strategies for in Vitro assessment of allegens: Sens-it-iv.

EUROPEAN COMMISSION

October 2005 - December 2010

Development of a two-dimensional gel electrophoresis based proteomics facility for protein discovery.

MEDICAL RESEARCH COUNCIL (MRC)

January 2001 - December 2001

Fluorescence Light Sheet Microscopy for Live 3D and 4D imaging

BIOTECHNOLOGY & BIOLOGICAL SCIENCE RESEARCH COUNCIL (BBSRC)

January 2014 - June 2014

The Molecular Basis of Adrenergic Regulation of Chemically-Induced Hepatotoxicity.

WELLCOME TRUST (UK)

September 2000 - October 2001

Centre for Drug Safety Science.

MEDICAL RESEARCH COUNCIL (MRC)

December 2008 - October 2014

Liverpool BioAFM: an integrated optical and atomic force microscope for research across the life sciences

BIOTECHNOLOGY & BIOLOGICAL SCIENCE RESEARCH COUNCIL (BBSRC)

January 2015 - January 2016

MRC in vivo capacity building studentships

BRITISH PHARMACOLOGICAL SOCIETY (UK)

October 2009 - September 2014

Synthesis and biological evaluation of primaquine metabolites: implications of safety and efficacy

MEDICINES FOR MALARIA VENTURE (SWITZERLAND)

July 2014 - July 2015

Role of inflammation in organ-selective off target adverse drug reactions

MINISTRY OF HIGHER EDUCATION (MALAYSIA)

July 2012 - June 2015

Department of Health Sponsored chair in pharmacogenetics.

DEPARTMENT OF HEALTH & SOCIAL CARE (UK) (DOH/DHSC/NIHR)

September 2007 - March 2019

Development of an in vivo model of drug-induced cutaneous toxicity.

WELLCOME TRUST (UK)

July 2001 - September 2001

The efficacy and safety of stem cell therapies in mouse models of kidney disease

DEPARTMENT FOR BUSINESS, INNOVATION AND SKILLS (UK)

January 2015 - January 2016

The response of the liver to chemical stress, a molecular and proteomic investigation of paracetamol-induced hepatotoxicity.

WELLCOME TRUST (UK)

September 2001 - September 2005

Mechanistic basis of dapsone hypersensitivity

ROYAL EMBASSY OF SAUDI ARABIA

July 2014 - June 2017

Utilisation of the COTOX trial to study the biological mechanisms of co-trimoxazole hypersensitivity in HIV disease.

MEDICAL RESEARCH COUNCIL (MRC)

January 1999 - January 2002

Cell culture laboratory.

WELLCOME TRUST (UK)

June 2000 - April 2001

SAFE-T

EUROPEAN COMMISSION

January 2011 - June 2015

Bridging and accelerating the translation of novel scientific findings for health and wealth gain

MEDICAL RESEARCH COUNCIL (MRC)

March 2014 - August 2015

Regenerative Medicine Platform in Stem Cell Safety Science

MEDICAL RESEARCH COUNCIL (MRC)

June 2013 - March 2018

The Chemical and Cellular Basis of Drug Hypersensitivity.

WELLCOME TRUST (UK)

January 2000 - January 2004

Tropical Resettlement Fellowship.

WELLCOME TRUST (UK)

October 1999 - September 2005

A prospective investigation of drug-specific B-cell responses in allergic patients with cystic fibrosis

UNIVERSITY OF ILORIN (NIGERIA)

December 2011 - November 2014

ARTEMIP - the safety pharmacology of artemisinins when used to reverse pathophysiology of malaria in pregnancy.

EUROPEAN COMMISSION

March 2008 - August 2011

Non-Attrition HAART nanoparticle therapies for HIV/AIDS Drug Delivery

ENGINEERING & PHYSICAL SCIENCES RESEARCH COUNCIL (EPSRC)

May 2009 - October 2012

A pharmacogenomic approach to coumarin anticoagulant therapy (PACT)

EUROPEAN COMMISSION

October 2008 - March 2013

An investigation on PZ mediated alterations in hepatocellular energy levels and mitochondrial function during APAP - induced hepatotoxicity.

WELLCOME TRUST (UK)

June 2006 - August 2006

Regulation of irinotecan anti-cancer pharmacology by Nrf2 – Implications for current use and potential for improved efficacy

NORTH WEST CANCER RESEARCH FUND

February 2014 - February 2016

Investigation of the role of Nrf2 in man

WELLCOME TRUST (UK)

October 2011 - May 2015

Liverpool Experimental Cancer Medicine Centre - DoH contribution

DEPARTMENT OF HEALTH & SOCIAL CARE (UK) (DOH/DHSC/NIHR)

April 2007 - March 2012

Mechanisms in biochemical pharmacology.

WELLCOME TRUST (UK)

October 1983 - September 2001

An investigation of the functional and regulatory role of GST-PI during chemical stress.

WELLCOME TRUST (UK)

September 2000 - April 2004

P-glycoprotein and efficacy of imatinib (Glivec).

ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST (UK)

June 2002 - October 2003

Liverpool Centre of Experimental Cancer Medicine.

CANCER RESEARCH UK (CRUK) (UK)

July 2007 - March 2012

Variability in response to warfarin: a prospective analysis of pharmacogenetic and environmental factors.

DEPARTMENT OF HEALTH & SOCIAL CARE (UK) (DOH/DHSC/NIHR)

September 2004 - October 2009

Capacity building award in integrative mammalian biology

BIOTECHNOLOGY & BIOLOGICAL SCIENCE RESEARCH COUNCIL (BBSRC)

January 2007 - October 2015

The immunological response consequences of metabolic drug activation by dendritic cells.

WELLCOME TRUST (UK)

April 2006 - April 2009

Definition of chemical and immunological signals associated with the development of contact dermatitis.

BRITISH SKIN FOUNDATION (UK)

January 2006 - December 2008

Analysis of inter-individual variation in the inducibility of the antioxidant response by Nrf2: an important element in the defence against cancer.

NORTH WEST CANCER RESEARCH FUND

May 2005 - April 2006

In vivo imaging technologies to assess the efficacy and safety of RMTs

MEDICAL RESEARCH COUNCIL (MRC)

October 2013 - March 2015

Liverpool Imaging Partnership: Molecular physiology and drug response

MEDICAL RESEARCH COUNCIL (MRC)

February 2013 - February 2017

YEAR 1 Wellcome Trust ISSF Non-Clinical Fellowships

WELLCOME TRUST (UK)

October 2011 - May 2018

Investigation into drug toxicity using high density array analysis corroborated with Northern Blot, real time PCR and RT-PCR.

WELLCOME TRUST (UK)

July 2001 - September 2001

Development of a transfected HepG2 cell line to study early signalling events following exposure to hepatotoxins.

MEDICAL RESEARCH COUNCIL (MRC)

September 2001 - August 2003

Chemical, clinical and molecular aspects of adverse drug reactions in man.

WELLCOME TRUST (UK)

January 1999 - August 2001

Pharmacogenetics of antimicrobial drug-induced liver injury.

DEPARTMENT OF HEALTH & SOCIAL CARE (UK) (DOH/DHSC/NIHR)

October 2004 - April 2008

Applying innovative technologies to improve the benefit-risk ratio of drugs: developing a national resource underpinned by the infrastructure of the MRC Centre for Drug Safety Science

MEDICAL RESEARCH COUNCIL (MRC)

April 2015 - March 2016

Investigation into the mechanisms of lamotrigine cutaneous toxicity.

MACMILLAN CANCER SUPPORT (UK)

February 1998 - March 2001

Positive Allosteric Modulators of Strychnine-Sensitive Glycine Receptors – A New Concept in Treating Chronic Pain

MEDICAL RESEARCH COUNCIL (MRC)

September 2012 - February 2015